Clinical Study Synopsis for Public Disclosure

Size: px
Start display at page:

Download "Clinical Study Synopsis for Public Disclosure"

Transcription

1 abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of the clinical study report - had been prepared in accordance with best practice and applicable legal and regulatory requirements at the time of study completion. The synopsis may include approved and non-approved uses, doses, formulations, treatment regimens and/or age groups; it has not necessarily been submitted to regulatory authorities. A synopsis is not intended to provide a comprehensive analysis of all data currently available regarding a particular drug. More current information regarding a drug is available in the approved labeling information which may vary from country to country. Additional information on this study and the drug concerned may be provided upon request based on s Policy on Transparency and Publication of Clinical Study Data. The synopsis is supplied for informational purposes only in the interests of scientific disclosure. It must not be used for any commercial purposes and must not be distributed, published, modified, reused, posted in any way, or used for any other purpose without the express written permission of. V1.0/2014

2 BI Trial No.: Page 3 Title of trial: Bioequivalence of 80 mg telmisartan/10 mg ramipril fixed-dose combination compared with the monocomponents, telmisartan and ramipril (two different formulations) given concomitantly to healthy male and female volunteers (an open-label, randomised, single-dose, three-way crossover study) Principal Investigator: Trial site: Publication (reference): Clinical phase: Objectives: Methodology: No. of subjects: planned: entered: 84 Data of this study have not been published I Germany To demonstrate the bioequivalence of 80 mg telmisartan/10 mg ramipril fixeddose combination versus its monocomponents given concurrently Open-label, randomised, single-dose, 6-sequence, 3-way crossover design actual: enrolled: 129 entered: 84 Test treatment: telmisartan and ramipril, fixed-dose combination entered: 84 treated: 83 analysed (for primary endpoint): 83 Diagnosis and main criteria for inclusion: Reference treatment 1: telmisartan (Micardis ) tablet + ramipril (Altace ) capsule entered: 84 treated: 84 analysed (for primary endpoint): 83 Reference treatment 2: telmisartan (Micardis ) tablet + ramipril (Delix ) tablet entered: 84 treated: 82 analysed (for primary endpoint): 82 Healthy male and female volunteers, age 18 and 55 years, body mass index (BMI) range: 18.5 and 29.9 kg/m 2

3 BI Trial No.: Page 4 Test product: Telmisartan and ramipril, fixed-dose combination tablet dose: 80 mg telmisartan/10 mg ramipril mode of admin.: Oral administration after an overnight fast of at least 10 hours, with 240 ml water batch no.: Reference therapy 1: dose: mode of admin.: batch no.: Reference therapy 2: dose: mode of admin.: batch no.: Duration of treatment: G67682 (B CTSS) Telmisartan (Micardis ) tablet and ramipril (Altace ) capsule 80 mg telmisartan and 10 mg ramipril Oral administration after an overnight fast of at least 10 hours, with 240 ml water Telmisartan (Micardis ): (B ), Ramipril (Altace ): (B ) Telmisartan (Micardis ) tablet and ramipril (Delix ) tablet 80 mg telmisartan and 10 mg ramipril Oral administration after an overnight fast of at least 10 hours, with 240 ml water Telmisartan (Micardis ): (B ), Ramipril (Delix ): N534 (B CTSS) Single dose during each of 3 consecutive treatment periods with sampling for 96 hours, followed by a 2-week washout period between treatments

4 BI Trial No.: Page 5 Criteria for evaluation: Efficacy / clinical pharmacology: Safety: Statistical methods: Bioequivalence of the telmisartan/ ramipril fixed-dose combination (FDC) and the monocomponents Micardis and Altace (Mic+Alt) and Micardis and Delix (Mic+Del) Primary endpoints: AUC 0- of telmisartan and ramiprilat (FDC, Mic+Alt, Mic+Del) and ramipril (FDC, Mic+Del); C max of telmisartan and ramiprilat (FDC, Mic+Alt, Mic+Del) and ramipril (FDC, Mic+Del); AUC 0-24 of telmisartan and ramiprilat (FDC, Mic+Alt, Mic+Del); AUC 0-tz of ramipril (FDC, Mic+Del) Secondary endpoints: AUC 0- of ramipril (Mic+Alt); C max of ramipril (Mic+Alt); AUC 0-tz of ramipril (Mic+Alt); t max, λ z, t 1/2, MRT po, CL/F, and V z /F of all analytes Comparison of treatments regarding bioequivalence was done in hierarchical order i.e.: 1. FDC versus Micardis plus Altace regarding telmisartan and ramiprilat AUCs and C max, if successful then 2. FDC versus Micardis plus Delix regarding telmisartan, ramiprilat and ramipril AUCs and C max, if successful then 3. Micardis plus Altace versus Micardis plus Delix regarding ramiprilat AUC and C max. If one of these comparisons failed than the successive tests were only descriptively interpreted. Physical examination, vital signs (blood pressure [BP], pulse rate [PR]), 12-lead electrocardiogram (ECG), clinical laboratory tests, adverse events (AEs), and tolerability Pharmacokinetic parameters of telmisartan, ramipril and ramiprilat were evaluated separately. The statistical model was an analysis of variance (ANOVA) on log transformed parameters including effects for 'sequence', 'subjects nested within sequences', 'period' and 'treatment'. Confidence intervals (CIs) were based on the residual error from ANOVA. Two-sided 90% CIs for the intra-subject ratio of telmisartan's and ramiprilat's AUC 0-, AUC 0-24, and C max, and ramipril's AUC 0-, AUC 0-tz, and C max were calculated to determine whether the CIs were contained in the acceptance range for bioequivalence (BE).

5 BI Trial No.: Page 6 BE regarding AUCs of telmisartan and AUCs and C max of ramiprilat and ramipril was assessed using the conventional acceptance range of %. As telmisartan is a highly variable drug, BE regarding C max of telmisartan was assessed using the extended acceptance range of %. For all other parameters, descriptive statistics were calculated. For all categorical parameters, frequencies were tabulated. SUMMARY CONCLUSIONS: Efficacy / clinical pharmacology results: For this trial, 129 healthy subjects were enrolled. Of these, 84 subjects were randomised. All randomised subjects received at least 1 dose of trial drug, forming the safety population. There were 2 discontinuations; all other 82 subjects (97.6% of the safety population) completed the study as planned. All but 1 of 84 subjects were white (98.8%); 56.0% of subjects were female. The mean (SD) age was 39.1 (10.2) years. There were no relevant medical history or concomitant medical conditions reported at baseline. Geometric mean plasma concentration-time profiles were superimposable for telmisartan and ramiprilat for all treatments; ramipril showed a delayed absorption for Mic+Alt treatment, compared with FDC and Mic+Del treatment. Comparable pre-dose ramiprilat concentrations were detected in period 2 and 3 for all treatments (FDC, Mic+Alt, Mic+Del). For the comparison of the FDC versus the monocomponent treatments for telmisartan, the adjusted gmean ratios (Test/Reference) and their 90% CIs were all contained in the acceptance range for bioequivalence of 80% to 125% (FDC vs. Mic+Alt: C max : 91.67% [84.00%, %], AUC 0- : 94.31% [89.90%, 98.94%], AUC 0-24 : 93.02% [89.21%, 96.99%]; FDC vs. Mic+Del: C max : 94.20% [86.29%, %], AUC 0- : 98.58% [93.95%, %], AUC 0-24 : 97.54% [93.53%, %]). For the comparison of the FDC with the monocomponents administered in a replicated design for telmisartan, the adjusted gmean ratios and their 90% CIs were all contained in the acceptance range for bioequivalence of 80% to 125% (FDC vs. free combinations: C max : 92.92% [86.22%, %], AUC 0- : 96.40% [92.18%, %], AUC 0-24 : 95.24% [91.61%, 99.01%]). For the comparison of the FDC with the monocomponent treatments for

6 BI Trial No.: Page 7 ramiprilat, the adjusted gmean ratios and their 90% CIs were all within the acceptance range for bioequivalence of 80% to 125% (FDC vs. Mic+Alt: C max : 99.35% [94.00%, %], AUC 0- : 98.55% [95.76%, %], AUC 0-24 : 97.96% [94.83%, %]; FDC vs. Mic+Del: C max : 95.57% [90.40%, %], AUC 0- : 99.92% [97.08%, %], AUC 0-24 : 96.41% [93.31%, 99.62%]). For the comparison of the FDC versus the monocomponents for ramipril, all adjusted gmean ratios and their 90% CIs were contained in the acceptance range for bioequivalence of 80% to 125% (FDC vs. Mic+Alt: C max : 93.07% [84.43%, %], AUC 0- : 93.67% [88.59%, 99.05%], AUC 0-tz : 93.28% [88.16%, 98.71%]; FDC vs. Mic+Del: C max : 93.13% [84.46%, %], AUC 0- : 93.42% [88.33%, 98.80%], AUC 0-tz : 93.15% [88.00%, 98.59%]). For the comparison between the 2 monocomponent treatments for ramiprilat and ramipril, all adjusted gmean ratios and their 90% CIs were contained in the acceptance range for bioequivalence of 80% to 125% (ramiprilat: C max : 96.20% [91.00%, %], AUC 0- : % [98.51%, %], AUC 0-24 : 98.42% [95.25%, %]; ramipril: C max : % [90.75%, %], AUC 0- : 99.73% [94.30%, %], AUC 0-tz : 99.85% [94.34%, %]). Female subjects had a higher telmisartan exposure and lower inter-individual variability than male subjects in all treatment periods. For the 3 treatments, the intra-individual variability was comparable for both female and male subjects; the adjusted gmean ratios and their 90% CIs were not different by gender. Safety results: Out of 84 randomised subjects, 82 subjects received all 3 planned doses of study medication (80 mg telmisartan/10 mg ramipril, administered as FDC, Mic+Alt, and Mic+Del). One subject discontinued after treatment period 2, receiving only 2 doses of 80 mg telmisartan/ 10 mg ramipril; another subject discontinued in the course of period 1, receiving only 1 dose of 80 mg telmisartan/10 mg ramipril. In this trial, 55 subjects (65.5%) reported at least 1 AE, including 2 subjects (2.4%) with AEs at screening, no subject with AEs in the post-study period, and 55 subjects (65.5%) with AEs during the treatment periods. The incidence of AEs was lower under FDC treatment (31.3%) than under the other treatments (Mic+Alt: 44.0%, Mic+Del: 37.8%). The most frequently reported AEs by preferred term were headache (32.1%),

7 BI Trial No.: Page 8 fatigue (28.6%), dizziness (21.4%), nausea (9.5%), and diarrhoea (8.3%). For headache, fatigue, and diarrhoea, the incidences were similar over treatments. Incidences of dizziness and nausea were lower under FDC treatment (dizziness: 3.6%, nausea: 0.0%) than under Mic+Alt treatment (dizziness: 11.9%, nausea: 4.8%), or Mic+Del treatment (dizziness: 11.0%, nausea: 7.3%). Most reported AEs were of mild intensity (39.3% overall; FDC: 24.1%, Mic+Alt: 32.1%, Mic+Del: 23.2%) or of moderate intensity (23.8% overall, FDC: 7.2%, Mic+Alt: 10.7%, Mic+Del: 13.4%). There were 2 subjects (2.4%) with severe AEs (Mic+Alt: 1 subject, Mic+Del: 1 subject). Forty-seven subjects (56.0%) reported AEs that were considered drug-related. The incidence of drug-related AEs was slightly lower under FDC treatment (24.1%) than under Mic+Alt treatment (32.1%) or Mic+Del treatment (30.5%). Under all treatments, headache, fatigue, and dizziness were the most frequent drug-related AEs. No death and no SAEs were reported. There occurred 1 other significant AE; the subject discontinued study participation (Mic+Alt, drug hypersensitivity). For several laboratory parameters, mean changes from baseline differed by >10% from baseline. In 1 subject in the FDC period, changes of laboratory values (number of neutrophils) were reported as AE (neutropenia). The mean blood pressure reduction from baseline was highest 8 hours after drug intake (systolic BP [SBP]/ diastolic BP [DBP], FDC: 17.0/ 14.3 mmhg, Mic+Alt: 14.9/ 13.2 mmhg, Mic+Del: 16.8/ 14.7 mmhg). The mean BP remained below baseline 24 hours after drug intake (FDC: 8.5/ 6.7 mmhg, Mic+Alt: 6.9/ 6.8 mmhg, Mic+Del: 8.6/ 7.7 mmhg), and returned to baseline at 96 hours after drug intake. In a number of subjects under all treatments, a SBP of <100 mmhg and/or DBP <60 mmhg was observed, which remained at a reduced level for up to 24 hours. A number of these subjects experienced AEs (preferred term: dizziness, headache, fatigue), which may have been related to the observed reduction in BP. Most of these AEs were of mild intensity; all of the subjects recovered from their AEs. The PR declined after intake of the study medication in all treatment periods, with the greatest decrease 4 hours after drug intake (mean change from baseline, FDC: 6.1 bpm, Mic+Alt: 7.6 bpm, Mic+Del: 5.8 bpm). The mean PR returned to baseline 24 hours after drug intake in all treatment periods. At 96

8 BI Trial No.: Page 9 hours after drug intake, PR values were increased (mean change from baseline, FDC: 6.4 bpm, Mic+Alt: 5.0 bpm, Mic+Del: 5.2 bpm). None of these changes were considered clinically relevant. The overall tolerability of subjects was mostly considered 'good' by the investigator (FDC: good =100.0% of subjects; Mic+Alt: good =97.6%, satisfactory =1.2%, not satisfactory =1.2%; Mic+Del: good =97.6%, satisfactory =2.4%). Overall, no clinically relevant safety issues were reported. Conclusions: This trial established the bioequivalence of a 80 mg telmisartan/10 mg ramipril fixed-dose combination (FDC) compared with the monocomponents, telmisartan and ramipril, given either as Micardis 80 mg plus Altace 10 mg or as Micardis 80 mg plus Delix 10 mg concurrently in healthy volunteers. Also, Altace 10 mg was shown to be bioequivalent to Delix 10 mg under coadministration of Micardis. The FDC was shown to be safe and well tolerated with a safety profile comparable to the monocomponents.

Clinical Study Synopsis for Public Disclosure

Clinical Study Synopsis for Public Disclosure abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of the clinical

More information

Clinical Study Synopsis for Public Disclosure

Clinical Study Synopsis for Public Disclosure abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of the clinical

More information

Clinical Study Synopsis for Public Disclosure

Clinical Study Synopsis for Public Disclosure abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of the clinical

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical

More information

Clinical Study Synopsis for Public Disclosure

Clinical Study Synopsis for Public Disclosure abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the

More information

Clinical Study Synopsis for Public Disclosure

Clinical Study Synopsis for Public Disclosure abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of the clinical

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the

More information

Clinical Study Synopsis for Public Disclosure

Clinical Study Synopsis for Public Disclosure abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of the clinical

More information

Clinical Study Synopsis for Public Disclosure

Clinical Study Synopsis for Public Disclosure abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of

More information

Clinical Study Synopsis for Public Disclosure

Clinical Study Synopsis for Public Disclosure abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of

More information

Clinical Study Synopsis for Public Disclosure

Clinical Study Synopsis for Public Disclosure abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the

More information

Clinical Study Synopsis for Public Disclosure

Clinical Study Synopsis for Public Disclosure abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of

More information

Clinical Study Synopsis for Public Disclosure

Clinical Study Synopsis for Public Disclosure abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of

More information

Clinical Study Synopsis for Public Disclosure

Clinical Study Synopsis for Public Disclosure abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis

More information

Clinical Study Synopsis for Public Disclosure

Clinical Study Synopsis for Public Disclosure abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of

More information

Clinical Study Synopsis for Public Disclosure

Clinical Study Synopsis for Public Disclosure abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace

More information

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the

More information

Clinical Study Synopsis for Public Disclosure

Clinical Study Synopsis for Public Disclosure abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical

More information

Study Centers: This study was conducted in 2 centers in Italy.

Study Centers: This study was conducted in 2 centers in Italy. Title of Trial: A randomised, double-blind, placebo-controlled, two-period, two-sequence-crossover interaction study to assess the effect of safinamide on levodopa pharmacokinetics in subjects with Parkinson

More information

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical

More information

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. SYNOPSIS Issue Date: 27 April 2009 Document No.: EDMS-PSDB-9908562:2.0 Name of Sponsor/Company Name of Finished Product Name of Active Ingredient Johnson & Johnson Pharmaceutical Research & Development,

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the

More information

Clinical Study Synopsis for Public Disclosure

Clinical Study Synopsis for Public Disclosure abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis

More information

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment:

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace

More information

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis

More information

PFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI

PFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.

More information

Clinical Study Synopsis for Public Disclosure

Clinical Study Synopsis for Public Disclosure abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace

More information

Study No. 178-CL-008 Report Final Version, 14 Dec 2006 Reissued Version, 18 Jul 2011 Astellas Pharma Europe B.V. Page 13 of 122

Study No. 178-CL-008 Report Final Version, 14 Dec 2006 Reissued Version, 18 Jul 2011 Astellas Pharma Europe B.V. Page 13 of 122 Page 13 of 122 3 SYNOPSIS Title of study: (International) Study No: A randomized, double-blind, parallel group, proof-of-concept study of in comparison with placebo and tolterodine in patients with symptomatic

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical

More information

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall

More information

PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert.

PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. Public Disclosure Synopsis Protocol A7772 September 25 Final PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert.

More information

2.0 Synopsis. ABT-333 M Clinical Study Report R&D/09/956

2.0 Synopsis. ABT-333 M Clinical Study Report R&D/09/956 2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: ABT-333 Volume: Name of Active Ingredient: Page: Sodium N-{6-[3-tert-butyl-5-(2,4-

More information

SYNOPSIS. Number of subjects: Planned: 22 Randomized: 23 Treated: 23. Evaluated: Pharmacodynamic: 22 Safety: 23 Pharmacokinetics: 22

SYNOPSIS. Number of subjects: Planned: 22 Randomized: 23 Treated: 23. Evaluated: Pharmacodynamic: 22 Safety: 23 Pharmacokinetics: 22 SYNOPSIS Title of the study: A randomized, cross-over, open, euglycemic clamp study on the relative bioavailability and activity of 0.6 U/kg insulin glargine and 20 µg lixisenatide, given as on-site mix

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the

More information

Clinical Trial Results Summary Study EN

Clinical Trial Results Summary Study EN Study Number: EN3288-113 Title of Study: A Double-blind, Dose-Ranging, Pilot Study to Evaluate the Safety, Subjective Effects, and Pharmacokinetics of Oxymorphone Hydrochloride in Healthy Subjects Who

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the

More information

Japanese, Korean and Chinese subjects had also lived outside their respective countries for less than 10 years.

Japanese, Korean and Chinese subjects had also lived outside their respective countries for less than 10 years. The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace

More information

Clinical Study Report AI Final 28 Feb Volume: Page:

Clinical Study Report AI Final 28 Feb Volume: Page: Study Design, Continued Electrocardiogram (ECG) and vital sign assessments were done at select times during the study. Blood and urine samples for clinical laboratory evaluations were collected at specified

More information

Treatment A Placebo to match COREG CR 20 mg OD + Lisinopril 10 mg OD (Days 1-7) Placebo to match COREG CR 40 mg OD + Lisinopril 10 mg OD (Days 8-14)

Treatment A Placebo to match COREG CR 20 mg OD + Lisinopril 10 mg OD (Days 1-7) Placebo to match COREG CR 40 mg OD + Lisinopril 10 mg OD (Days 8-14) The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Product: Cinacalcet hydrochloride Clinical Study Report: Page 2 of 670

Product: Cinacalcet hydrochloride Clinical Study Report: Page 2 of 670 Page 2 of 670 2. SYNOPSIS Name of Sponsor: mgen Inc., Thousand Oaks, C Name of Finished Product: Cinacalcet hydrochloride (Sensipar, Mimpara ) Name of ctive Ingredient: cinacalcet (cinacalcet hydrochloride

More information

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the

More information

2. SYNOPSIS Name of Sponsor/Company:

2. SYNOPSIS Name of Sponsor/Company: in patients with refractory partial seizures 14 Jun 2007 2. SYNOPSIS TITLE OF STUDY: Efficacy and safety of BIA 2-093 as adjunctive therapy for refractory partial seizures in a double-blind, randomized,

More information

SYNOPSIS. Study centre(s) The study was performed in Denmark, Norway and Sweden at 20 sites.

SYNOPSIS. Study centre(s) The study was performed in Denmark, Norway and Sweden at 20 sites. Drug substance(s): AZD0837 Edition No.: 1 Study code: D1250C00007 Date: 22 May, 2006 SYNOPSIS (For national authority use only) A Controlled, Randomised, Parallel, Multicentre Study to Assess Safety and

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical

More information

INDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER

INDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER 2. SYNOPSIS Title of Study: An Open-Label, 2-Cohort Study to Evaluate the 2-Way Interaction Between Multiple Doses of and a Single Dose of Rosuvastatin (Crestor ), to Assess the Dose Proportionality of,

More information

Principal Investigator: Marion, Alan, S, M.D., MDS Pharma Services (US) Inc., 621 Rose Street, PO Box 80837, Lincoln, NE 68502, USA

Principal Investigator: Marion, Alan, S, M.D., MDS Pharma Services (US) Inc., 621 Rose Street, PO Box 80837, Lincoln, NE 68502, USA SYNOPSIS Issue Date: 06 October 2008 Document No.: EDMS-PSDB-8954363:2. Name of Sponsor/Company Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Name of Finished Product Name of Active Ingredient(s)

More information

Hydrocodone/Acetaminophen Extended-Release Tablets M Clinical Study Report R&D/09/1109

Hydrocodone/Acetaminophen Extended-Release Tablets M Clinical Study Report R&D/09/1109 2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: ABT-712 Volume: Hydrocodone/Acetaminophen Extended-Release Name

More information

(For National Authority Use Only) Name of Study Drug: to Part of Dossier:

(For National Authority Use Only) Name of Study Drug: to Part of Dossier: 2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: Volume: Vicodin CR Name of Active Ingredient: Page: Hydrocodone/Acetaminophen

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace

More information

IRBES_R_04320 Generic drug name: Irbesartan + amlodipine Date: Study Code: 31 active centers: 20 in Korea, 7 in India and 4 in Philippines.

IRBES_R_04320 Generic drug name: Irbesartan + amlodipine Date: Study Code: 31 active centers: 20 in Korea, 7 in India and 4 in Philippines. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinicalTrials.gov

More information

PFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI.

PFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI. PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.

More information

Individual Study Table Referring to Part of the Dossier. Volume:

Individual Study Table Referring to Part of the Dossier. Volume: Final Report M/100977/21Final Version () 2. SYNOPSIS A Title of Study: A PHASE IIa, RANDOMISED, DOUBLE-BLIND, MULTIPLE DOSE, PLACEBO CONTROLLED, 3 PERIOD CROSS-OVER, ASCENDING DOSE CLINICAL TRIAL TO ASSESS

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis

More information

SYNOPSIS. Publications No publications at the time of writing this report.

SYNOPSIS. Publications No publications at the time of writing this report. Drug product: TOPROL-XL Drug substance(s): Metoprolol succinate Study code: D4020C00033 (307A) Date: 8 February 2006 SYNOPSIS Dose Ranging, Safety and Tolerability of TOPROL-XL (metoprolol succinate) Extended-release

More information

Principal Investigator: Robert J. Jones, MD, Beatson Cancer Center, 1053 Great Western Road, Glasgow; United Kingdom

Principal Investigator: Robert J. Jones, MD, Beatson Cancer Center, 1053 Great Western Road, Glasgow; United Kingdom SYNOPSIS Issue Date: 14 October 2010 Document No.: EDMS-ERI-13494974:2.0 Name of Sponsor/Company Name of Finished Product Name of Active Ingredient(s) Protocol No.: COU-AA-BE Cougar Biotechnology, Inc.

More information

Sponsor: Sanofi Drug substance(s): SAR342434

Sponsor: Sanofi Drug substance(s): SAR342434 These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor: Sanofi Drug substance(s):

More information

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace

More information

Final Report (Amendment 1) April 11, 2006 Page 4 of 50

Final Report (Amendment 1) April 11, 2006 Page 4 of 50 Page 4 of 50 2 SYNOPSIS Title: A Bioavailability Study to Assess the Bioequivalence of Alfacalcidol Capsule and Oral Drop Formulations: A Comparative, Randomized, Single-Dose, 4-Way Crossover Bioavailability

More information

Summary ID# Clinical Study Summary: Study B4Z-MC-LYBU

Summary ID# Clinical Study Summary: Study B4Z-MC-LYBU CT Registry ID#7065 Page 1 Summary ID# 7065 Clinical Study Summary: Study B4Z-MC-LYBU A Randomized, Double-Blind Comparison of Atomoxetine Hydrochloride Augmented with Either Extended-Release Methylphenidate

More information

Study No Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Study Endpoints: Pharmacokinetics:

Study No Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Study Endpoints: Pharmacokinetics: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace

More information

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall

More information

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

SYNOPSIS. Issue Date: 31 July 2013

SYNOPSIS. Issue Date: 31 July 2013 SYNOPSIS Issue Date: 31 July 2013 Name of Sponsor/Company Name of Finished Product Name of Active Ingredient(s) Janssen Research & Development, LLC YONDELIS Trabectedin (R279741) Protocol No.: ET743-OVC-1003

More information

SYNOPSIS Final Clinical Study Report for Study AI444031

SYNOPSIS Final Clinical Study Report for Study AI444031 Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Name of Active Ingredient: () Individual Study Table Referring to the Dossier (For National Authority Use Only) SYNOPSIS for Study

More information

Results. Subject Disposition and Demographics Of 37 enrolled subjects, 23 (62.2%) completed the study

Results. Subject Disposition and Demographics Of 37 enrolled subjects, 23 (62.2%) completed the study Poster 5-20 Effect of Gastric ph on the Bioavailability of in Healthy Subjects James Longstreth, PhD, Marijke H. Adams, PharmD, PhD, 2 Vasi Sperry, PhD, 3 Dan Kajdasz, PhD, 3 Carol R. Reed, MD 3 Longstreth

More information

Study No: LOV OMA-104 Title : Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Statistical Methods

Study No: LOV OMA-104 Title : Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Statistical Methods The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study Center(s): The study was conducted at 39 study sites in Japan.

Study Center(s): The study was conducted at 39 study sites in Japan. SYNOPSIS Issue Date: 20 NOVEMBER 2012 Name of Sponsor/Company Janssen Pharmaceutical K. K. Name of Finished Product CONCERTA Name of Active Ingredient(s) Methylphenidate HCl Protocol No.: JNS001-JPN-A01

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace

More information

SYNOPSIS 2/198 CSR_BDY-EFC5825-EN-E02. Name of company: TABULAR FORMAT (For National Authority Use only)

SYNOPSIS 2/198 CSR_BDY-EFC5825-EN-E02. Name of company: TABULAR FORMAT (For National Authority Use only) SYNOPSIS Title of the study: A randomized, double-blind, placebo-controlled, parallel-group, fixed-dose (rimonabant 20 mg) multicenter study of long-term glycemic control with rimonabant in treatment-naïve

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical

More information

Summary ID# Clinical Study Summary: Study B4Z-MC-LYCL

Summary ID# Clinical Study Summary: Study B4Z-MC-LYCL CT Registry ID#8226 Page 1 Summary ID# 8226. Clinical Study Summary: Study B4Z-MC-LYCL Guiding Dose Increases in Patients Incompletely Responsive to Usual Doses of Atomoxetine by Determining Plasma Atomoxetine

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace

More information

Summary ID# Clinical Study Summary: Study B4Z-JE-LYBC

Summary ID# Clinical Study Summary: Study B4Z-JE-LYBC CT Registry ID# 5285 Page 1 Summary ID# 5285 Clinical Study Summary: Study B4Z-JE-LYBC A Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Comparison of Fixed-Dose Ranges of Hydrochloride

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the

More information

Principal Investigator and Study Center: F. Nobuoka, MD Ageo Medical Clinic, 3133 Haraichi, Ageo City, Saitama , Japan

Principal Investigator and Study Center: F. Nobuoka, MD Ageo Medical Clinic, 3133 Haraichi, Ageo City, Saitama , Japan Page 1 APPENDIX 9: ZRHM-PK-05-JP CLINICAL STUDY SUMMARY The study was conducted in Japan from August to November 2013. Principles as defined in International Conference on Harmonization (ICH) Good Clinical

More information

Principal Investigator. Study center(s) This was a single-center study. Publications None at the time of writing this report.

Principal Investigator. Study center(s) This was a single-center study. Publications None at the time of writing this report. (For national authority SYNOPSIS use only) Date 3 March 2005 An open, randomized, two-way crossover study evaluating the pharmacokinetics of budesonide and formoterol from Symbicort pmdi versus Oxis Turbuhaler

More information